Study to Evaluate Study Drug XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)
Enrolling By Invitation
18 years - 99 years
All
1 Location
Brief description of study
The primary purposes of this research study are to determine the safety and tolerability of dose levels of the investigational drug, XmAb20717, and if XmAb20717 works in treating advanced solid tumors that have progressed after treatment with standard cancer therapies or solid tumors for which there are no appropriate therapies available.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: advanced solid tumors
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 829993
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
